Analytical Data
-
Gene name
CSTA
- Application
-
Alternative Names
CSTA；STF1；STFA;Cystatin-A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01040
-
Expression Region
1-98aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MIPGGLSEAK PATPEIQEIV DKVKPQLEEK TNETYGKLEA VQYKTQVVAG TNYYIKVRAG DNKYMHLKVF KSLPGQNEDL VLTGYQVDKN KDDELTGF
-
Molecular Weight
13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CSTA, or cystatin A, is a member of the cystatin superfamily of proteins, which are known for their role as cysteine protease inhibitors. Research into CSTA has gained significant interest due to its potential implications in various physiological and pathological processes, including inflammation, cancer progression, and neurodegenerative diseases. Abnormal expression levels of CSTA have been observed in several malignancies, suggesting that it may serve as a biomarker for tumor progression or response to therapy. Moreover, its function in regulating proteolytic activities makes it crucial for maintaining cellular homeostasis and immune responses. Recent advances in recombinant protein technology have enabled the production of CSTA in sufficient quantities for in-depth structural and functional analyses, providing insights into its mechanism of action and interactions with other biomolecules. Understanding the structure-function relationship of CSTA could offer new therapeutic avenues for diseases where protease activity is dysregulated. Overall, the study of recombinant CSTA not only facilitates a deeper understanding of its biological roles but also opens up possibilities for its application in clinical diagnostics and targeted therapies.
